Blue Abstract Wave Banner

Key Information

Chief Investigator Sejal Saglani

ICTU Collaboration: Operations; Statistics; Database

Email: TREAT_trial@imperial.ac.uk

Website: TREAT trial

Trial registration: ISRCTN 12109108  EudraCT 2019-004085-17

Status:  Recruiting

A multi-centre, parallel arm, randomised, open label, controlled, non-inferiority trial of mepolizumab and omalizumab with a run-in to identify Severe Therapy Resistant Asthma (STRA) and Refractory Difficult Asthma.

The trial aims to recruit 500 children with severe asthma aged six to sixteen years into the initial Run-in phase and 150 participants to proceed into the randomised phase which lasts for 52 weeks. Recruited eligible participants will be randomised (1:1) to either omalizumab or mepolizumab

 

 

 

Therapeutic areas contacts

For contact details please visit Therapeutic areas contacts